ACCESS Newswire (Fri, 7-Aug 8:35 AM ET)
XBIO Prices $4.5 Million Offering: What the Capital Raise Signals for Investors
Market Chameleon (Fri, 10-Oct 5:38 AM ET)
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
Xenetic Biosciences trades on the NASDAQ stock market under the symbol XBIO.
As of September 10, 2026, XBIO stock price declined to $4.07 with 13,435 million shares trading.
XBIO has a beta of -0.34, meaning it tends to be less sensitive to market movements. XBIO has a correlation of 0.00 to the broad based SPY ETF.
XBIO has a market cap of $9.54 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, XBIO traded as high as $13.93 and as low as $1.90.
The top ETF exchange traded funds that XBIO belongs to (by Net Assets): VXF.
XBIO has outperformed the market in the last year with a price return of +31.2% while the SPY ETF gained +17.7%. XBIO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +32.0% and +5.4%, respectively, while the SPY returned +3.1% and -1.1%, respectively.
XBIO support price is $3.98 and resistance is $4.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XBIO shares will trade within this expected range on the day.
